| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
4008200310 |
| Email: |
marketing@tsbiochem.com |
| Products Intro: |
Product Name:PAT-048
CAS:1359983-15-5
Package:1removed
|
PAT-048 manufacturers
- PAT-048
-
- $2800.00 / 100mg
-
2026-04-21
- CAS:1359983-15-5
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | PAT-048 Basic information |
| Product Name: | PAT-048 | | Synonyms: | PAT-048;Benzoic acid, 3-[[6-chloro-7-fluoro-2-methyl-1-(1-propyl-1H-pyrazol-4-yl)-1H-indol-3-yl]thio]-2-fluoro-;PAT 048,PAT048 | | CAS: | 1359983-15-5 | | MF: | C22H18ClF2N3O2S | | MW: | 461.91 | | EINECS: | | | Product Categories: | | | Mol File: | 1359983-15-5.mol |  |
| | PAT-048 Chemical Properties |
| storage temp. | Store at -20°C | | solubility | Soluble in DMSO |
| | PAT-048 Usage And Synthesis |
| Description | PAT-048 is a type III Autotaxin inhibitor. | | Uses | PAT-048 is a potent, selective and orally active autotaxin inhibitor, inhibits IL-6 mRNA expression, but shows no effect on autotaxin protein and pulmonary lysophosphatidic acid (LPA) production in lung fibrosis model. PAT-048 shows an IC50 and IC90 of 20 nM and 200 nM for autotaxin in mouse plasma. PAT-048 reduces dermal fibrosis in vivo[1][2]. | | References | [1] Castelino FV, et al. An Autotaxin/Lysophosphatidic Acid/Interleukin-6 Amplification Loop Drives Scleroderma Fibrosis. Arthritis Rheumatol. 2016 Dec;68(12):2964-2974. DOI:10.1002/art.39797
[2] Black KE, et al. Autotaxin activity increases locally following lung injury, but is not required for pulmonary lysophosphatidic acid production or fibrosis. FASEB J. 2016 Jun;30(6):2435-50. DOI:10.1096/fj.201500197R |
| | PAT-048 Preparation Products And Raw materials |
|